The US FDA is weighing whether patents covering digital applications used with approved drugs should be listed in the “Orange Book” as part of the agency’s efforts to modernize the compendium.
In a Jan. 30 announcement about new guidance and other initiatives aimed at making the Orange Book a more useful...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?